“`html
Key Facts
Stanley Druckenmiller, a renowned investor and head of Duquesne Family Office, sold all his shares in Nvidia (NASDAQ: NVDA) and Palantir Technologies (NASDAQ: PLTR), stocks that saw gains of 1,400% and 2,300% over the past three years, respectively. He exited Nvidia in Q3 of last year and Palantir earlier this year.
In contrast, Druckenmiller recently increased his holdings in Eli Lilly (NYSE: LLY), owning 100,675 shares after initially purchasing 62,190 shares in Q4 of last year, and opened a new position in Viking Therapeutics (NASDAQ: VKTX) with 549,295 shares in Q2 of this year. The weight loss drug market is projected to grow from $28 billion today to $95 billion by 2030.
Eli Lilly reported a 54% increase in revenue attributed to its weight loss portfolio, underscoring the significant demand in this market. Viking Therapeutics is in late-stage development for a weight loss candidate, indicating potential future growth.
“`
